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Abstract
AIM: To investigate whether whole-exome sequencing 
may serve as an efficient method to identify known or 
novel colorectal cancer (CRC) predisposing genes in 
early-onset or familial CRC cases.
METHODS: We performed whole-exome sequencing 
in 23 Chinese patients from 21 families with non-
polyposis CRC diagnosed at ≤ 40 years of age, or from 
multiple affected CRC families with at least 1 first-
degree relative diagnosed with CRC at ≤ 55 years of 
age. Genomic DNA from blood was enriched for exome 
sequences using the SureSelect Human All Exon Kit, 
version 2 (Agilent Technologies) and sequencing was 
performed on an Illumina HiSeq 2000 platform. Data 
were processed through an analytical pipeline to 
search for rare germline variants in known or novel 
CRC predisposing genes.
RESULTS: In total, 32 germline variants in 23 genes 
were identified and confirmed by Sanger sequencing. 
In 6 of the 21 families (29%), we identified 7 mutations 
in 3 known CRC predisposing genes including MLH1 (5 
patients), MSH2 (1 patient), and MUTYH (biallelic, 1 
patient), five of which were reported as pathogenic. In 
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the remaining 15 families, we identified 20 rare and novel 
potentially deleterious variants in 19 genes, six of which 
were truncating mutations. One previously unreported 
variant identified in a conserved region of EIF2AK4 
(p.Glu738_Asp739insArgArg) was found to represent a 
local Chinese variant, which was significantly enriched in 
our early-onset CRC patient cohort compared to a control 
cohort of 100 healthy Chinese individuals scored negative 
by colonoscopy (33.3% vs  7%, P < 0.001).
CONCLUSION: Whole-exome sequencing of early-on-
set or familial CRC cases serves as an efficient method 
to identify known and potential pathogenic variants 
in established and novel candidate CRC predisposing 
genes.
Key words: Colorectal cancer; Cancer predisposition; 
Early-onset; Germline variants; Exome sequencing
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: Mendelian colorectal cancer (CRC) predis-
position syndromes underlie about 5% of all CRCs, 
and are caused by germline mutations in a limited set 
of genes. The overall heritability of CRC, however, is 
estimated to be approximately 30% and as yet many 
families at risk remain unexplained. This research 
identifies seven mutations of known CRC predisposing 
genes (MLH1 , MSH2 and MUTYH ) in 6 of the 21 
families (29%), five of which were previously reported 
as pathogenic. One unreported variant EIF2AK4 (p.G
lu738_Asp739insArgArg) located at conserved region 
was found to represent a local Chinese variant and 
significantly enriched in our early-onset CRC patient 
cohort.
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INTRODUCTION
Colorectal cancer (CRC; MIM 114500) is the third 
most common cancer worldwide and the fourth 
leading cause of cancer-related death, with over 
one million new cases diagnosed and approximately 
600000 deaths each year[1]. In China, it is the third 
most common cancer and the fifth leading cause of 
death from cancer. Moreover, the incidence of CRC in 
China has been increasing in recent years[2]. Genetic 
factors are estimated to account for the development 
of approximately 30% of all CRC cases[3]. However, 
Mendelian colorectal cancer predisposition syndromes, 
such as Lynch syndrome (LS), familial adenomatous 
polyposis (FAP), MUTYH-associated polyposis (MAP), 
juvenile polyposis syndrome (JPS) and polymerase 
proofreading-associated polyposis (PPAP), account 
for only approximately 5%-10% of all CRC cases 
and are associated with high-penetrance germline 
mutations in various mismatch repair (MMR) genes or 
the APC, MUTYH, SMAD4, BMPR1A, POLE and POLD1 
genes, respectively[4,5]. The remaining approximately 
20%-25% of the cases are thought to be due to 
moderate- to low-penetrance variants, most of which 
remain to be identified.
CRC patients with a family history of CRC or 
an early age at diagnosis are especially suggestive 
of a hereditary contribution and may be used in 
genetic association studies to increase the likelihood 
of identifying susceptibility variants[6-10]. Whereas 
CRC families with multiple affected individuals may 
be employed to search for high penetrance genetic 
susceptibility variants using linkage-based approaches, 
moderate- to low-penetrance variants cannot be 
identified through linkage-based studies in large 
families. In more recent years, multiple low-penetrance 
genetic loci associated with CRC susceptibility have 
been identified by genome-wide association studies 
(GWAS)[11,12]. However, not all results from linkage 
studies turned out to be consistent, and GWAS are 
not ideal for the identification of rare variants. Recent 
advances in next-generation sequencing (NGS) 
technologies, in particular whole-exome sequencing, 
have provided efficient means to identify germline 
variants in individuals with familial or inherited cancer 
syndromes[5,13-15]. We hypothesized that the majority 
of the yet unidentified CRC predisposing variants can 
be identified using whole-exome sequencing when 
applied to a strictly selected cohort of CRC patients and 
families. Several cellular signaling pathways appear to 
be involved in the development of CRC, including the 
WNT, DNA repair, BMP/TGF-β, apoptosis, MMIF/GIF, 
and PI3K/AKT pathways[16]. In addition, “sleeping 
beauty” transposon tagging has recently been em-
ployed as an effective forward genetic screening tool 
for the discovery of novel cancer initiating genes in the 
mouse intestinal tract, resulting in the identification of 
hundreds of novel candidate cancer driver genes[17-19].
In this study, we aimed to identify rare and novel 
germline variants in known and novel candidate CRC 
predisposing genes by performing whole-exome 
sequencing of germline DNA of 23 Chinese patients 
from 21 families diagnosed with non-polyposis CRC at 
a young age. We initially focused on genes that, based 
on genetic and functional data, are likely to play a role 
in CRC development, and on candidate genes that 
have been identified through GWAS studies.
MATERIALS AND METHODS
Recruitment of patient and control cohorts
Twenty-three patients from 21 families included in 
this study were recruited through the Department of 
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Gastroenterology of the General Hospital of Beijing 
Military Region, Beijing, China. All patients were 
diagnosed with CRC without polyposis at ≤ 40 years 
of age[20] or from multiple affected CRC families with at 
least one first-degree relative diagnosed with CRC at 
≤ 55 years of age. Additionally, 100 colonoscopy test-
negative, unrelated controls with Chinese Han ancestry 
without inflammatory bowel disease or any family 
history of CRC were collected from a subject pool who 
participated in health check-up programs, including 
colonoscopy, at the department of Gastroenterology of 
the General Hospital of Beijing Military Region, Beijing, 
China. This study was approved by the Institutional 
Review Board of the General Hospital of Beijing Military 
Region (No. 2014-035), and all patients have provided 
written informed consent.
Whole-exome sequencing
Genomic DNA was extracted from peripheral blood 
cells using a QIAamp DNA Kit (QIAGEN, Hilden, 
Germany) according to the protocol provided by the 
manufacturer and whole-exome sequencing was 
performed at the Beijing Genome Institute (BGI, 
Shenzhen, China) according to manufacturer’s guide-
lines. Briefly, genomic DNA was fragmented and 
enriched for exome sequences using the SureSelect 
Human All Exon Kit, version 2 (Agilent Technologies, 
Santa Clara, CA, United States) and sequencing was 
performed at a minimal average coverage of 50 × on 
an Illumina HiSeq 2000 platform (Illumina, Inc., San 
Diego, CA).
Bioinformatics analyses
After removing sequence adaptors and low-quality 
reads, Burrows-Wheeler Aligner (BWA)[21] was used to 
align the reads to the NCBI human reference genome 
(hg19). Single nucleotide variants (SNVs) were called 
using SOAPsnp[22] and small insertion/deletions (indels) 
were detected using the SAMtools software package[23]. 
All variants were annotated using an in-house annotation 
pipeline, as described previously[24]. High-confidence 
variants (total ≥ 10 reads, ≥ 5 variant reads and ≥ 
20% variant reads) were subsequently prioritized for 
variants that were non-synonymous and not found 
in our in-house database (1302 in-house analyzed 
exomes, mostly from European ancestry). In addition, 
dbSNPv138, the National Heart, Lung, and Blood 
Institute (NHLBI) Exome Sequencing Project database 
(ESP, 6503 exomes, http://evs.gs.washington.edu/
EVS/), and 700 control exome data sets from Chinese 
subjects with Han ancestry (Juan Tian and Zhimin Feng, 
BGI, personal communication) were used to exclude 
recurrent variants with a minor allele frequency (MAF) 
> 0.001.
Functional impact of variant analyses
Non-synonymous variants that result in alterations in 
protein function, including protein truncation, splice site 
defects and missense mutations at highly conserved 
(phyloP ≥ 3.0) nucleotide positions, were included in our 
analyses. Alamut v.2.0 software (Interactive Biosoftware) 
and integrated mutation prediction software (align 
GVDV, SIFT and PolyPhen-2)[25-27] packages were used 
for analyses of the identified variants. The prediction of 
splicing effects was evaluated based on five different 
algorithms (SpliceSiteFinder, MaxEntScan, NNSPLICE, 
GeneSplicer, Human Splicing Finder) through the 
bioinformatics tools of the Alamut v.2.0 software. 
The online tool “Project HOPE”[28] (http://www.cmbi.
ru.nl/hope/) was used for revealing the structural 
consequences of missense mutations. 
Candidate gene selection
We initially selected germline variants in CRC 
predisposing genes known to be associated with 
hereditary CRC syndromes and searched for evidence 
of pathogenicity in relevant databases, i.e., InSiGHT 
(http://www.insight-group.org/), LOVD (https://atlas.
cmm.ki.se/LOVDv.2.0/) and the Mismatch Repair 
Genes Variant Database (http://www.med.mun.ca/
mmrvariants/). 
Next to the identification of variants in known 
CRC predisposing genes, we searched for potential 
pathogenic variants in novel candidate genes using the 
remaining exome data of our CRC patient cohort. For 
the selection of these variants, we focused on genes 
that meet the following criteria: (1) genes exhibiting 
recurrent variants; (2) 582 known cancer genes, 
including somatically mutated cancer genes (Cancer 
Gene Census, http://www.sanger.ac.uk/genetics/CGP/
Census/)[29,30], cancer predisposing genes of which 
rare germline variants are known to confer a highly 
or moderately increased risk of cancer and for which 
at least 5% of individuals with the relevant variants 
develop cancer[31], and genes that are included in the 
Radboud university medical center hereditary cancer 
gene list[32]; (3) 286 genes that have been identified as 
candidate CRC driver genes by the “sleeping beauty” 
transposon tagging system in mice[18,19]; (4) 588 
genes included in the following KEGG pathways: WNT 
signaling pathway (hsa04310), TGF-β signaling pathway 
(hsa04350), base excision repair (BER, hsa03410), 
nucleotide excision repair (NER, hsa03420), mismatch 
repair (MMR, hsa03430), non-homologous end-joining 
(NHEJ, hsa03450), Fanconi anemia pathway (hsa03460) 
and pathways involved in cancer (hsa05200); and (5) 
268 genes likely to play a role in CRC susceptibility 
identified by GWAS studies[11,12,33,34] and included in 
the NHGRI GWAS Catalog (http://www.genome.gov/
gwastudies/)[35].
Variant validation by Sanger sequencing
Identified germline variants were validated by Sanger 
sequencing after PCR amplification. The PCR primers 
were designed in silico using the Primer3 software 
package[36]. PCR reactions were performed on a Dual 
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Table 1  Clinical characteristics and family histories of 23 early-onset and familial colorectal cancer patients
96-Well GeneAmp PCR System 9700 (Applied Bio-
systems) using standard protocols (primer sequences 
available upon request). Mutation analyses were 
performed using the Vector NTI software package 
(Invitrogen, Paisley, United Kingdom).
RESULTS
Patient cohort characteristics
In order to identify known and potential pathogenic 
variants in established and novel candidate CRC 
predisposing genes, we performed whole-exome 
sequencing on germline DNA of 23 CRC patients from 
21 families with non-polyposis CRC diagnosed at ≤ 
40 years of age (n = 16), or from multiple affected 
CRC families with at least one first-degree relative 
diagnosed with CRC at ≤ 55 years of age (n = 7). The 
mean age at diagnosis was 38.6 years, and 43% (n = 
10) of the patients were female (Table 1). 
Exome sequencing performance
Overall, we generated a mean of 68 M raw reads per 
sample, of which 77.6% to 89.5% were aligned to the 
human reference genome (hg19; Table 2). The mean 
coverage of the exome for the 23 samples was 58.5
× (range: 53.0-64.7×). On average, 87.03% of the 
reads was covered at least 10 times and 76.35% of 
the reads was covered at least 20 times.
We identified on average 46437 SNVs (range: 
44353-48114) and 1678 indels (range: 1630-1719) 
per exome. Over 95.3% of these substitutions and 
73.1% of indels represented known variants listed in 
private and public databases (Figure 1). A prioritization 
scheme was applied to identify candidate variants 
(Table 3). Initial quality filtering (total ≥ 10 reads, ≥ 
5 variant reads and ≥ 20% variant reads) resulted in 
the identification of 13819 genetic variants in coding 
regions or canonical splice sites, including 9833 non-
synonymous changes. A total of 4432 variants that 
result in alterations in protein function, including 172 
nonsense variants, 188 frame shift variants, 943 
canonical splice site variants, 237 in-frame deletions, 
191 in-frame insertions and 2701 missense variants 
with high conservation scores (phyloP ≥ 3.0), were 
identified. Subsequently, we excluded known variants 
present in our in-house database and variants with MAF 
scores > 0.001 in dbSNPv138, reducing the number of 
variants to 2883. Subsequently, we prioritized variants 
in known CRC predisposing genes and in genes likely to 
play a role in CRC development, and excluded variants 
with MAF scores > 0.1 in the ESP database or in the 
700 control exomes from Chinese subjects with Han 
ancestry, thereby reducing the number of candidate 
variants to 61. Of these 61, 39 (32 different variants in 
23 genes) were validated by Sanger sequencing (Figure 2).
Identification of germline variants in known CRC 
predisposing genes
A total of seven CRC patients from six families (30%) 
were identified with germline variants in known CRC 
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Patient ID Gender Patient's history Family history
43-1A Female RC at 37 yr Brother RC at 53 yr
43-2A Male RC at 53 yr Sister RC at 37 yr
49-4A Male CC at 30 yr Brother CC at 43 yr; sister CC at 23 yr
49-5A Female CC at 23 yr Brother CC at 43 yr; brother CC at 30 yr
50-11A Male CC at 34 yr and relapse at 36 Father CRC at 35 yr and death at 52 yr; brother CC at 34 yr and death at 36 yr
54-2A Female RC at 44 yr Sister CRC; Brother CC at 76 yr and death
66-1-1A Female CC at 47 yr Sister CC at 51 yr
71A Female RC at 57 yr Sister RC at 53 yr
77-1A Female CRC at 38 yr Father EC at 64 yr and death; uncle CRC at 68 yr and death
102-1A Male RC at 25 yr
103-1A Male CC at 53 yr Brother CC at 36 yr and death at 48 yr; mother IO at 63 yr and death
106-2A Male JC at 34 yr, CC at 39 yr, KC at 44 
yr and PC at 45 yr
Father EC and death; mother RC at 42 yr and death; Sister CP
108-1A Male RC at 33 yr
110-1A Male CC at 36 yr
116-1A Female CC at 31 yr and HC at 57 yr Brother intussusception and death at 40 yr; Brother CC at 50 yr, RC and SMT at 58 yr; brother IC 
at 50 yr, CC at 53 yr and RC at 61 yr; sister GC at 56 yr
120-1A Female RC at 36 yr
142-1A Male RC at 34 yr
149-1A Male CRC at 31 yr Father EC and death, mother GC at 56 yr
154-1A Female CRC at 40 yr Father HC, RC and death at 57 yr
156-1A Female CRC at 54 yr Sister CP at 54 yr; sister CP; mother CC at 48 yr; grandfather EC and death.
164-1A Male CC at 30 yr Uncle colonitls at 42 yr
165-1A Male CRC at 43 yr Sister RC at 31 yr and death; grandmother RC at 65 yr and death.
180-1 Male CRC at 40 yr Sister CP at 46 yr
CRC: Colorectal cancer; CC: Colon cancer; RC: Rectal cancer; IC: Ileocecus carcinoma; IO: Intestinal obstruction; JC: Jejunum cancer; KC: Kidney cancer; PC: 
Pulmonary carcinoma; CP: Colonic polyps; HC: Hepatic carcinoma; GC: Gastric cancer; EC: Esophageal cancer; SMT: Splenic metastatic tumors.
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Table 2  Alignment and coverage statistics for 23 early-onset and familial colorectal cancer patients
predisposing genes. Of these, five variants (in four 
patients) were reported as being pathogenic in public 
databases, three of which were located in MLH1[37] 
(Table 4), including a canonical splice site mutation 
(c.453+1G>T) in patient 106-2A (colon cancer at 
age of 39), a canonical splice site mutation (c.208-
1G>A) in patient 116-1A (colon cancer at age of 31), 
and a missense mutation (c.677G>A, p.Arg226Gln) in 
patient 43-1A (rectal cancer at age of 37). This latter 
mutation has been reported to result in a complete 
skipping of exon 8 at the mRNA level[38]. The brother of 
patient 43-1A was also subjected to exome sequencing 
(patient 43-2A, rectal cancer at age of 53), but the 
MLH1 mutation c.677G>A was not encountered in 
this patient, and subsequent Sanger sequencing 
confirmed this finding. Compound heterozygous MUTYH 
mutations (p.Gln267* and p.Gly286Glu) were found in 
patient 180-1 (CRC at age of 40). The sister of patient 
180-1 (colonic polyps at age of 46) also carried both 
MUTYH mutations (p.Gln267* and p.Gly286Glu). Both 
mutations have been reported to be causative for 
MUTYH-associated polyposis (MAP)[39,40].
Three mismatch repair gene mutations, observed in 
three unrelated patients, were not previously reported 
in public databases. A novel splice site mutation in 
MSH2 (c.793-2A>T) was identified in patient 50-11A 
(colon cancer at age of 34). This canonical splice 
site is inactivated and a splice site seven nucleotides 
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Sample ID Total reads Total mapped Reads mapped to 
genome
Covered ≥ 4× Covered ≥10× Covered ≥ 20× Average target 
coverage
43-1A 62997602 52130593 45528212 93.30% 85.80% 74.30% 55.88×
43-2A 57099664 50367772 43924906 93.60% 86.40% 75.00% 54.94×
49-4A 67025248 51978393 45418701 93.30% 85.70% 74.10% 55.30×
49-5A 60632336 51598017 45450431 92.60% 85.00% 73.40% 55.49×
50-11A 68991044 58507454 51033221 94.00% 87.20% 76.80% 60.71×
54-2A 68459832 57860336 50820626 93.40% 86.50% 76.10% 61.71×
66-1-1A 69759994 58838035 51472112 94.10% 87.60% 77.50% 61.82×
71A 68055130 58181783 51012277 94.00% 87.60% 77.70% 61.50×
77-1A 65956248 56894265 49817369 93.80% 87.30% 77.10% 61.06×
102-1A 64702600 57086284 49672873 94.40% 87.90% 77.70% 59.92×
103-1A 66004146 55109962 48218769 93.80% 86.90% 76.40% 59.28×
106-2A 61956558 54367359 47567033 93.80% 86.80% 76.00% 57.97×
108-1A 64764180 56469665 49473520 94.00% 87.20% 76.50% 57.52×
110-1A 68883264 56962439 49975545 94.10% 87.30% 76.90% 59.31×
116-1A 68975484 60681318 53305706 93.70% 86.70% 75.60% 55.86×
120-1A 64307066 56593051 49900259 94.20% 87.30% 75.90% 53.02×
142-1A 72999930 65321752 57822754 94.70% 87.60% 76.20% 53.19×
149-1A 69636008 59789305 52641740 93.90% 87.20% 76.90% 61.19×
154-1A 80632788 63934448 56196297 94.40% 88.30% 78.90% 64.69×
156-1A 94340904 82125696 73199086 94.20% 87.10% 76.10% 56.48×
164-1A 67813680 58837471 51779826 93.60% 86.50% 75.80% 58.83×
165-1A 68657326 59845292 52561646 94.30% 87.80% 77.70% 60.99×
180-1 65727112 57908057 50742938 94.40% 87.90% 77.50% 59.01×
Average 68190354 58321250 51197211 93.90% 87.03% 76.35% 58.51×
Figure 1  Variant statistics (marked in colors) for 23 early-onset colorectal cancer patient samples. The numbers of detected variants are listed on the left hand 
side and the patient samples ID on the bottom. The different colors represent different types of variants, i.e., purple represents “private indels”, green represents “private 
SNVs”, red and blue represent known indels and known SNVs listed in the 1000 genome, dbSNPv138 and in-house databases, respectively. SNV: Single nucleotide 
variant.
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Table 3  Prioritization scheme for exome data analysis of all 23 patients
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Type of prioritization filter Remaining variants (n )
All variants 1106642
Coding region and canonical splice site variants after quality filtering (total ≥ 10 reads, ≥ 5 variant reads and 
≥ 20% variant reads)
    13819
Non-synonymous variants, canonical splice site variants       9833
Variants that result in alterations in protein function (protein truncation, splice site defects and missense 
mutations at highly conserved (phyloP ≥ 3.0) nucleotide positions.
Not in in-house database and MAF ≤ 0.001 in dbSNPv138
       44321
      2883
Variants in known CRC predisposing genes and genes likely to play a role in CRC development (MAF ≤ 0.001 
in ESP and 700 control Chinese exome data sets)
          61
Variants/genes validated by Sanger sequencing 39 (32 different variants in 23 genes)
1Including 172 nonsense variants, 188 frame shift variants, 943 canonical splice site variants, 237 in-frame deletions, 191 in-frame insertions and 2701 
missense variants with highly conserved (phyloP ≥ 3.0); In-house database: 1302 in-house analyzed exomes, mostly from European ancestry. MAF: Minor 
allele frequency; ESP: Exome Sequencing Project database (6503 exomes, http://evs.gs.washington.edu/EVS/); 700 control Chinese exome data sets: 
Chinese subjects with Han ancestry (Juan Tian and Zhi-Min Feng, BGI, personal communication).
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Figure 2  Germline variants identified in known colorectal cancer predisposing genes and genes likely to play a role in colorectal cancer development. 
The genes are listed on the left hand side and the patient samples on top. Patient samples from the same families are marked (bars). Known colorectal cancer (CRC) 
predisposing genes are marked by shading (left). The shades at the right hand side of the figure indicate functional (groups of) genes considered to play a role in CRC 
development. The different variant types are indicated in colors (right). The red-triangle/green-triangle square in sample 180-1 indicates the presence of one MUTYH 
nonsense and one MUTYH missense mutation.
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Table 4  Identification of germline mutations in known colorectal cancer predisposing genes
downstream is used according to Alamut prediction. 
Both a frame shift mutation in MLH1 (p.Arg389Profs*6) 
and a missense variant in MSH6 (p.Thr767Ser) were 
found in patient 49-4A (colon cancer at age of 30). 
The MLH1 mutation p.Arg389Profs*6 was also found 
in his sister, patient 49-5A (colon cancer at age of 
23), whereas this sister was found to be negative for 
the MSH6 variant p.Thr767Ser. Segregation analysis 
of four siblings and the mother in this family (Figure 
3) showed that the brothers of index patient 49-4A, 
i.e., family members Ⅱ:1 (colon cancer at age of 43 
years) and Ⅱ:3 (no cancer), carried both mutations. 
The MLH1 p.Arg389Profs*6 mutation-positive, MSH6 
wild-type mother I:2 and the MLH1 wild-type, MSH6 
p.Thr767Ser variant-positive brother Ⅱ:4 both did not 
develop cancer. We, therefore, conclude that the MLH1 
frame shift mutation (p.Arg389Profs*6) acts as the 
main contributor to the development of CRC in this 
family.
Rare germline variants of novel candidate CRC 
predisposing genes
After extrusion of variants in known CRC predisposing 
genes, a set of 24 rare candidate germline variants 
remained (Table 5). Of these, seven represent truncating 
mutations (five frame-shift indels, one nonsense and 
one canonical splice site). In addition, one in-frame 
insertion and 16 highly conserved non-synonymous 
missense variants are present in this set. For these latter 
variants, SIFT and Polyphen2 algorithms were used 
to estimate their functional effects on the respective 
encoded proteins. In all cases, both SIFT and Polyphen2 
predicted the variants to be functionally impaired or 
possibly/probably functionally impaired (Table 6). Four 
rare or novel variants were found in cancer predisposing 
genes that are not directly linked to an increased CRC 
risk, including ATM p.Lys468Glufs*18 in patient 102-1A 
(rectal cancer at age of 25 years), MAX p.Leu61Serfs*15 
in patient 66-1-1A (colon cancer at age of 47 years), 
TSC2 p.Asp1734Asn in patient 164-1A (colon cancer 
at age of 30 years) and ETV4 p.Glu331Lys in patient 
71A (rectal cancer at age of 57 years). ATM and MAX 
are involved in DNA repair pathways, and TSC2 plays 
a role in the PI3K/AKT pathway. These pathways are 
also active in CRC. Interestingly, in patient 66-1-1A we 
also observed a potentially deleterious variant in PARP1 
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Sample ID Gene name Gene ID Genomic change cDNA change Protein change Pathogenicity
43-1A MLH1 NM_000249 g.chr3:37053590G>A c.677G>A1 p.Arg226Glna    Yes[38,44]
106-2A MLH1 NM_000249 chr3:g.37048555G>T c.453+1G>T SSM Yes[42]
116-1A MLH1 NM_000249 g.chr3:37042445G>A c.208-1G>A SSM Yes[43]
180-1 MUTYH NM_001128425 g.chr1:45797972G>A c.799C>T p.Gln267* Yes[39]
180-1 MUTYH NM_001128425 g.chr1:45797914C>T c.857G>A p.Gly286Glu Yes[40]
49-4A MLH1 NM_000249 g.chr3:37067252_37067253insT c.1163_1164insT p.Arg389Profs*6 NR
49-5A MLH1 NM_000249 g.chr3:37067252_37067253insT c.1163_1164insT p.Arg389Profs*6 NR
49-4A MSH6 NM_000179 g.chr2:48027422C>G c.2300C>G p.Thr767Ser NR
50-11A MSH2 NM_000251 g.chr2:47641406A>T c.793-2A>T SSM NR
1This substitution results in a complete loss of exon 8 of MLH1 by RNA analysis[38]. NR: Not reported; SSM: Splice site mutation.
Family 49
Ⅰ:1 Ⅰ:2
+ MLH1 p.Arg389Profs*6
- MSH6 p.Thr767Ser
Ⅱ:1 Colon cancer, at age of 43 yr
Ⅱ:1 (49-4A) Colon cancer, at age of 30 yr
Ⅱ:1 (49-4A) Colon cancer, at age of 23 yr
+                     -                    -                    -                     +                    + MLH1 p.Arg389Profs*6
+                     -                    +                    +                    +                     - MSH6 p.Thr767Ser
Ⅱ:1                 Ⅱ:2                Ⅱ:3                Ⅱ:4                Ⅱ:5                 Ⅱ:6 
49-4A              49-5A
Figure 3  Pedigree and segregation analysis in family members of index patients for MLH1 and MSH6 mutations. Index patients are indicated by arrows. Both 
index patients Ⅱ:5 (sample 49-4A) and Ⅱ:6 (sample 49-5A) carried MLH1 frame shift mutation (c.1163_1164insT, p.Arg389Profs*6) and Ⅱ:5 also carried MSH6 
missense mutation (c.2300C>G, p.Thr767Ser). Two brothers Ⅱ:1 (colon cancer at age of 43) and Ⅱ:3 (no cancer) carried both mutations. A sister (Ⅱ:2, no cancer) 
carried neither the MLH1 nor the MSH6 mutation. A third brother (Ⅱ:4) carried the MSH6 mutation, but not the MLH1 mutation. And the mother of index patients 
carried MLH1 mutation, but not the MSH6 mutation. Both did not develop cancer.
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Table 5  Characteristics of 24 variants identified in 19 novel genes likely to play a role in colorectal cancer development
(p.Lys254Glufs*6), another gene involved in DNA repair.
Genes recurrently affected by potentially deleterious 
variants
Despite the limited size of our cohort, the recurrent 
detection of rare potentially deleterious variants is 
another way to select candidates from the list of rare 
variants. Four genes were found to be recurrently 
affected by different rare variants, and two of them 
(BUB1 and LRP5) were encountered in patients that 
also carried pathogenic MLH1 mutations (patients 
106-2A and 43-1A, respectively; Figure 2). In total, 
two truncating BUB1 variants were found (p.Gln16* 
and p.Gln949Argfs*3). As reported previously, these 
BUB1 variants may be associated with an increased 
risk for aneuploidy and, in patient 106-2A, this may 
have contributed to somatic loss of the wild-type MLH1 
allele in the tumor[15]. The other recurrently affected 
genes were LRP5, RPS6KB2 and RYR2. LRP5 may be 
of particular interest since it is a component of the 
WNT-FZD-LRP5-LRP6 complex that triggers β-catenin 
signaling through the induction of aggregation of 
receptor-ligand complexes into ribosome-sized 
signalsomes. We identified three highly conserved LRP5 
missense variants in three unrelated patients (Figure 
2). Two of these, p.Tyr719Cys and p.Arg1179His, 
were found to be located in the conserved low-density 
lipoprotein (LDLR) class B repeat region. To investigate 
the functional consequences of these three mutations 
on the LRP5 protein structure, the online tool “Project 
HOPE” was used. By doing so, we found that variant 
p.Tyr719Cys gives rise to a mutant residue that is 
smaller and more hydrophobic than the wild-type 
residue, which may lead to loss of protein-protein 
interactions and hydrogen bonds and/or disturb 
correct protein folding. Through variant p.Arg1179His, 
a positively charged residue is replaced by a neutral 
and smaller residue, which again may lead to loss of 
interactions with other molecules or residues. Through 
variant p.Arg1307Trp, a positively charged residue is 
replaced by a neutral, larger and more hydrophobic 
residue, which may lead to loss of interactions with 
other molecules or residues, loss of hydrogen bonds 
and/or disturbance of correct protein folding giving rise 
to collisions with other molecules or residues.
We also identified a recurrent insertion in EIF2AK4 (
p.Glu738_Asp739insArgArg) in seven (33.3%) unrelated 
patients, which was absent in local in-house and public 
databases. EIF2AK4 is located in a region previously 
found to be associated with CRC susceptibility in GWAS 
studies[11,35]. Since this variant could be common in the 
Han Chinese population, we screened a cohort of 100 
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Sample ID Gene 
name
Gene/pathway involved cDNA change Protein change rs ID in 
dbSNP138
MAF (700 
Chinese 
exomes)
MAF 
(NHLBI 
ESP)
MAF 
(1000 
genome)
102-1A ATM Cancer gene, DNArep c.1402_1403del p.Lys468Glufs*18 NR NR NR NR
66-1-1A PARP1 DNArep c.758dup p.Lys254Glufs*6 NR NR 0.000077 NR
66-1-1A MAX Cancer gene c.181del p.Leu61Serfs*15 NR NR NR NR
106-2A BUB1 Cancer gene c.46C>T p.Gln16* NR NR NR NR
149-1A BUB1 Cancer gene c.2844del p.Gln949Argfs*3 NR NR NR NR
165-1A LIG3 DNArep c.218del p.Phe73Serfs*41 NR NR NR NR
54-2A MCC Transposon studies c.1355+1_1355+2ins14 SMM NR NR NR NR
49-4A EIF2AK4 GWAS related c.2214_2215insCGACGA p.Glu738_Asp739insArgArg NR NR NR NR
71A EIF2AK4 GWAS related c.2214_2215insCGACGA p.Glu738_Asp739insArgArg NR NR NR NR
103-1A EIF2AK4 GWAS related c.2214_2215insCGACGA p.Glu738_Asp739insArgArg NR NR NR NR
108-1A EIF2AK4 GWAS related c.2214_2215insCGACGA p.Glu738_Asp739insArgArg NR NR NR NR
120-1A EIF2AK4 GWAS related c.2214_2215insCGACGA p.Glu738_Asp739insArgArg NR NR NR NR
154-1A EIF2AK4 GWAS related c.2214_2215insCGACGA p.Glu738_Asp739insArgArg NR NR NR NR
164-1A EIF2AK4 GWAS related c.2214_2215insCGACGA p.Glu738_Asp739insArgArg NR NR NR NR
77-1A LRP5 WNT c.2156A>G p.Tyr719Cys NR NR NR NR
43-1A LRP5 WNT c.3536G>A p.Arg1179His NR NR 0.000077 NR
54-2A LRP5 WNT c.3919C>T p.Arg1307Trp NR NR 0.000077 NR
110-1A RPS6KB2 PI3K/AKT c.331A>G p.Lys111Glu NR 0.00075 NR NR
43-1A RPS6KB2 PI3K/AKT c.683C>A p.Thr228Asn rs183360785 NR NR 0.001
43-1A RYR2 Somatic mutation gene c.2701G>A p.Gly901Ser NR NR NR NR
103-1A RYR2 Somatic mutation gene c.6457A>G p.Lys2153Glu NR NR NR NR
102-1A RYR3 Somatic mutation gene c.13507G>A p.Val4503Met NR NR NR NR
71A ETV4 Cancer gene c.991G>A p.Glu331Lys NR NR NR NR
103-1A PRDM1 Cancer gene c.1499A>G p.Gln500Arg rs201512476 NR NR 0.001
164-1A TSC2 Cancer gene, PI3K/AKT c.5200G>A p.Asp1734Asn NR NR NR NR
71A MTOR PI3K/AKT c.5857G>T p.Val1953Leu NR 0.000714 NR NR
154-1A DAAM1 WNT c.667G>A p.Val223Met NR NR NR NR
71A FZD10 WNT c.1341C>G p.Phe447Leu NR NR NR NR
164-1A TCF7 WNT c.572G>T p.Arg191Met NR NR NR NR
71A MAST2 Transposon studies c.3482A>G p.Asn1161Ser NR NR 0.000077 NR
MAF: Minor allele frequency; NR: Not reported; DNArep: DNA repair pathway; WNT: WNT signaling pathway; SSM: Splice site mutation.
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Table 6  In silico  functional prediction of 16 missense variants
colonoscopy test-negative, unrelated local Han Chinese 
individuals using Sanger sequencing. We found that 
7 (7%) of them carried this variant, revealing a 
significant enrichment in the early-onset/familial CRC 
cohort as compared to the ethnicity matched control 
cohort (χ 2 test, P = 0.000604).
DISCUSSION
In order to identify rare and novel germline variants 
that may predispose to CRC, we applied whole-exome 
sequencing to 23 Chinese patients from 21 families 
with non-polyposis CRC diagnosed at ≤ 40 years of 
age or from multiple affected CRC families with at least 
one first-degree relative diagnosed with CRC at ≤ 55 
years of age. Initially we selected variants in genes 
that are known to be associated with hereditary CRC 
syndromes, and we assessed their pathogenicity as 
reported in public databases such as InSiGHT, LOVD and 
the Mismatch Repair Genes Variant database. Among 
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Sample ID Gene 
name
Gene/
pathway 
involved
cDNA 
change
Protein change Domain PhyloP 
score
Grantham 
score
Align 
GVGD
SIFT 
score
SIFT 
prediction
Polyphen2 
score
Polyphen2 
prediction
77-1A LRP5 WNT c.2156A>G p.Tyr719Cys LDLR class 
B repeat
4.751 194 C65 0.000 D 0.999 PrD
43-1A LRP5 WNT c.3536G>A p.Arg1179His LDLR class 
B repeat
3.712   29 C25 0.000 D 0.953 PrD
54-2A LRP5 WNT c.3919C>T p.Arg1307Trp LDLR class 
A repeat
3.172 101 C35 0.000 D 0.948 PrD
110-1A RPS6KB2 PI3K/
AKT
c.331A>G p.Lys111Glu Protein 
kinase, 
catalytic 
domain
4.639   56 C55 0.000 D 0.535 PoD
43-1A RPS6KB2 PI3K/
AKT
c.683C>A p.Thr228Asn Protein 
kinase, 
catalytic 
domain
5.062   65 C55 0.001 D 0.994 PrD
43-1A RYR2 Somatic 
mutation 
gene
c.2701G>A p.Gly901Ser Ryanodine 
receptor
6.081   56 C55 0.010 D 1.000 PrD
103-1A RYR2 Somatic 
mutation 
gene
c.6457A>G p.Lys2153Glu Intracellular 
calcium-
release 
channel
5.067   56 C0 0.020 D 0.615 PoD
102-1A RYR3 Somatic 
mutation 
gene
c.13507G>A p.Val4503Met Ryanodine 
Receptor 
TM 4-6
6.012   21 C15 0.000 D 1.000 PrD
71A ETV4 Cancer 
gene
c.991G>A p.Glu331Lys PEA3-type 
ETS-domain 
transcrip-
tion factor, 
N-terminal
6.424   56 C55 0.001 D 0.862 PoD
103-1A PRDM1 Cancer 
gene
c.1499A>G p.Gln500Arg Zinc finger, 
C2H2
4.875   43 C0 0.050 D 0.570 PoD
164-1A TSC2 Cancer 
gene, 
PI3K/
AKT
c.5200G>A p.Asp1734Asn Rap/ran-
GAP
5.538   23 C0 0.000 D 0.998 PrD
71A MTOR PI3K/
AKT
c.5857G>T p.Val1953Leu PIK-related 
kinase
5.634   32 C0 0.001 D 0.827 PoD
154-1A DAAM1 WNT c.667G>A p.Val223Met Diaphanous 
GTPase-
binding
6.347   21 C0 0.000 D 0.998 PrD
71A FZD10 WNT c.1341C>G p.Phe447Leu Frizzled 
protein
4.229   22 C15 0.000 D 0.984 PrD
164-1A TCF7 WNT c.572G>T p.Arg191Met High mobil-
ity group, 
HMG1/
HMG2
4.202   91 C65 0.000 D 0.999 PrD
71A MAST2 Trans-
poson 
studies
c.3482A>G p.Asn1161Ser PDZ/
DHR/
GLGF
4.854   46 C0 0.000 D 0.999 PrD
D: Damaging; PoD: Possibly damaging; PrD: Probably damaging.
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the 23 patients included, we identified seven patients 
(from six families; approximately 30%) with variants 
in known CRC predisposing genes. This percentage 
is lower than that previously reported by Tanskanen 
et al[41], (42%, 16/38) in a cohort of early-onset CRC 
patients (< 40 years) using exome sequencing. In a 
study by Tanskanen et al[41], of 38 patients, four were 
clinically diagnosed with gastrointestinal polyposis 
(three FAP and one JPS), and 12 were identified with 
germline MMR mutations and enriched in patients with 
MSI tumors (86%, 12/14). This discrepancy may be 
due to the fact that our cohort is a non-polyposis cohort 
and also includes patients from multiple affected CRC 
families with at least one first-degree relative diagnosed 
with CRC at ≤ 55 years of age. In our cohort, six 
patients were identified with variants in the high-
penetrance genes MLH1, MSH2 and MSH6 underlying 
Lynch syndrome. In addition, we identified biallelic 
MUTYH mutations, underlying MAP, in one index patient 
(patient 180-1, CRC at age of 40) and the sister of 
the patient (colonic polyps at age of 46). Of the eight 
variants that we identified in known high-penetrance 
CRC predisposing genes, MLH1 c.453+1G>T, MLH1 
c.208-1G>A, MLH1 c.677G>A, MUTYH p.Gln267* 
and MUTYH p.Gly286Glu were reported as being 
pathogenic in public databases[39,40,42-44]. In addition, 
we identified novel rare variants of which two, MLH1 p. 
Arg389Profs*6 and MSH2 c.793-2A>T, are most likely 
pathogenic based on both familial segregation and in 
silico prediction analyses.
In our search for novel germline predisposing 
variants, we focused on known cancer-associated 
genes, CRC pathway-associated genes, mouse CRC 
susceptibility genes identified by transposon (‘sleeping 
beauty’) tagging, GWAS-associated genes and genes 
with reported somatic mutations that are considered 
likely to be involved in CRC predisposition and/or 
development. Using these criteria, we identified a total 
of 19 novel candidate CRC susceptibility genes carrying 
rare, likely deleterious, variants.
One ATM truncating variant (p.Lys468Glufs*18) 
identified in patient 102-1A (rectal cancer at age of 25) 
may be particularly relevant. ATM is a gene encoding 
a protein that belongs to the PI3/PI4-kinase family[45]. 
The ATM protein represents an important cell cycle 
checkpoint kinase that is required for a cell’s response 
to DNA damage and for ensuring genomic integrity[46]. 
Diseases associated with ATM mutations include ataxia 
telangiectasia (AT), an autosomal recessive disorder[47]. 
Because of its role in maintaining genomic integrity, 
ATM may, when mutated, increase the risk for tumor 
development[48]. Indeed, germline mutations in ATM 
have been shown to increase the risk of breast cancer 
development through the (de)regulation of BRCA1[49]. 
In addition, loss of heterozygosity at the ATM locus 
has been found in CRC[50]. Taken together, it appears 
plausible to assume that germline ATM mutations 
may increase the risk for CRC development. However, 
considering the high frequency of truncating mutation 
in ESP database and in-house database, it is crucial for 
targeted screening of ATM in a large early-onset and/or 
familial CRC cohort. Another interesting candidate is the 
truncating MAX variant (p.Leu61Serfs*15) identified 
in patient 66-1-1A. The protein encoded by the MAX 
gene represents the most conserved dimerization 
component of the MYC-MAX-MXD1 network of basic 
helix-loop-helix leucine zipper (bHLHZ) transcription 
factors that regulate cellular proliferation, differentiation 
and apoptosis[51,52]. It has been shown that the MAX 
protein interacts with MSH2[53], and that mutant MAX 
is able to alter the growth and morphology of CRC 
cells through inactivation of c-MYC[32]. Mutations in the 
MAX gene have been reported to be associated with 
the occurrence of hereditary pheochromocytomas 
and paragangliomas[54]. Interestingly, an additional 
truncating variant in PARP1 (p.Lys254Glufs*6) was 
identified in this patient (66-1-1A). PARP1 is activated 
in response to DNA damage and plays an important 
role in DNA repair processes, apoptosis and cell cycle 
control[55]. Since MAX and PARP1 are both involved in 
DNA repair, and since it has been shown that PARP1 
is essential for c-MYC-induced transactivation and 
retardation of the G2-M transition in cancer cells[56], 
the combination of these two variants may have a 
synergistic effect. Therefore, we anticipate that both 
truncating variants most likely play a role in CRC 
development in this family.
Other interesting candidate genes recurrently affected 
by potentially deleterious variants include BUB1, LRP5 
and EIF2AK4. Two truncating variants in BUB1 (p.Gln16* 
and p.Gln949Argfs*3) were found to be present in 
patient 106-2A and patient 149-1A, respectively. The 
BUB1 protein is an integral component of the spindle 
assembly checkpoint (SAC), and we have previously 
shown that germline variants in the corresponding 
gene may serve as risk factors for CRC[15]. Patient 
106-2A was found to carry both BUB1 p.Gln16* and 
MLH1 c.453+1G>T variants. We suggest that BUB1 
may have contributed to loss of the wild-type MLH1 
allele in this patient[15]. Obviously, this latter scenario 
requires validation in larger CRC cohorts.
Three missense LRP5 variants (p.Tyr719Cys, 
p.Arg1179His and p.Arg1307Trp), found in three 
CRC cases, were predicted to be deleterious. LRP5 
p.Tyr719Cys and LRP5 p.Arg1307Trp were observed in 
patient 54-2A and patient 77-1A, respectively. In both 
cases no other putative pathogenic germline variants 
were detected. Variant LRP5 p.Arg1179His was found 
in patient 43-1A, who also carried a pathogenic MLH1 
c.677G>A splice site mutation. The LRP5 protein is 
a component of the WNT-FZD-LRP5-LRP6 complex 
and, as such, represents an important partner in the 
WNT signal transduction pathway[57]. Variants LRP5 
p.Tyr719Cys and p.Arg1179His are both located 
in the conserved low-density lipoprotein receptor 
(LDLR) class B repeat region of LRP5, which is the 
binding region of Dickkopf-1, a developmental protein 
antagonist of the canonical WNT-β-catenin pathway[58]. 
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Further assessment of both LRP5 variants using the 
“Project HOPE” tool indicated that these variants may 
also result in loss of interactions with other proteins 
or residues. It has previously been shown that trun-
cated LRP5 proteins are frequently expressed in 
breast tumors of different developmental stages[59] 
and that these proteins are strongly implicated in the 
deregulation of the WNT-β-catenin signaling pathway 
in hyperparathyroid tumors[60].
One EIF2AK4 variant (p.Glu738_Asp739insArgAr
g) was recurrently found in seven (33.3%) unrelated 
patients within our cohort. After comparison of our cohort 
to an ethnicity matched control cohort, this variant was 
found to be significantly enriched (P = 0.000604). We, 
therefore, conclude that also this latter gene may be 
considered a candidate CRC predisposing gene.
A major challenge of using whole-exome sequencing 
is the identification of predisposing pathogenic variants 
within the vast background of non-pathogenic variants. 
Targeted screening of those genes and variants in 
replicate large early-onset and/or familial CRC cohorts 
will be instrumental in gaining more robust evidence 
for pathogenicity. Our current results, however, already 
vividly illustrate that whole-exome sequencing in 
carefully selected cases at risk for hereditary cancer 
may serve as an attractive approach to identify rare 
and novel variants in known and novel candidate CRC 
predisposing genes.
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Background
Mendelian colorectal cancer (CRC) predisposition syndromes underlie about 
5% of all CRC cases, and are caused by germline mutations in a limited set 
of genes. The current selection of causative genes to be screened in high-risk 
families is based on several phenotypic characteristics, including polyposis 
(e.g., APC and MUTYH) and microsatellite instability (MLH1, MSH2, MSH6 
and PMS2). The overall heritability of CRC, however, is estimated to be 
approximately 30%. Excluding hereditary forms, there is an important fraction of 
CRC cases that present familial aggregation for the disease with an unknown 
germline genetic cause.
Research frontiers
CRC patients with a family history of CRC or an early age at diagnosis are 
especially suggestive of a hereditary contribution and may be used in genetic 
association studies to increase the likelihood of identifying susceptibility 
variants. Whereas CRC families with multiple affected individuals may be 
employed to search for high penetrance genetic susceptibility variants using 
linkage-based approaches, moderate- to low-penetrance variants cannot be 
identified through linkage-based studies in large families. In more recent years, 
multiple low-penetrance genetic loci associated with CRC susceptibility have 
been identified by genome-wide association studies (GWAS). However, not 
all results from linkage studies turned out to be consistent, and GWAS are 
not ideal for the identification of rare variants. Recently, advances in next-
generation sequencing technologies, in particular whole-exome sequencing, 
have provided efficient means to identify germline variants in individuals with 
familial or inherited cancer syndromes.
Innovations and breakthroughs
A major challenge of using whole-exome sequencing is the identification of 
predisposing pathogenic variants within the vast background of non-pathogenic 
variants. In this study, we performed whole-exome sequencing in a strictly 
selected cohort of CRC patients and families that are very young CRC patients 
(diagnosed at ≤ 40 years of age) or familial CRC cases. And data were 
processed through a tailored analytical pipeline to search for rare germline 
variants in known or novel CRC predisposing genes.
Applications
The study show that whole-exome sequencing of early-onset or familial CRC 
cases serves as an efficient method to identify known and potential pathogenic 
variants in established and novel candidate CRC predisposing genes. The 
findings also provide insight into the role of these variants in CRC development. 
Targeted screening of those genes and variants in replicate large early-
onset and/or familial CRC cohorts will be instrumental in gaining more robust 
evidence for pathogenicity.
Terminology
“Early-onset” CRC: CRC is traditionally thought to be a disease of older 
patients with most being diagnosed after the age of 50 years; however, a 
significant proportion of young patients present with this disease. Early age of 
onset is a central characteristic of hereditary predisposition to cancer. Familiar 
aggregation of tumors and hereditary cases are constantly more frequent under 
the age of 40 years.
Peer-review
This study investigated the efficiency of whole-exome sequencing in identifying 
known or novel CRC predisposing genes in early-onset or familial CRC cases. 
This is a well written paper that has been performed stringently. Although the 
number of included patients is very low, the authors present very interesting 
results with a straight forward conclusion.
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